(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
7 Fast Approaches to Let loose Space on Your Telephone in a flash - 2Grasping the Elements of Medical caretaker Pay rates: Factors That Shape Your Pay
- 3Germany's Deutsche Welle broadcaster declared 'undesirable' in Russia
- 45 Great Youngster Care Administrations To Watch in 2024
- 57 Heavenly Espressos, One Do You Like?
- Instructions to Keep up with Your Traded Teeth for Life span
- A hunger for new experiences Narratives: Motivating Travel and Experience
- This Tiny Neon Frog Dwells in the Clouds
- Figure out how to Guarantee Your Dental Embeds Endure forever
- Hostile to Maturing Skincare Items to Rejuvenate Your Skin
- The Advancement and Effect of Dental Embed Innovation on Oral Wellbeing
- Audits of the Top Science fiction Movies This Year
- Pick Your Favored method of transportation
- People can't get enough of this couple's Hallmark movie reviews. They don't know the painful backstory.
